Synapse Open Synapse
Business

Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

Financial Times ·

Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector

Latest from Financial Times